BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12474225)

  • 1. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.
    Olsburgh J; Harnden P; Weeks R; Smith B; Joyce A; Hall G; Poulsom R; Selby P; Southgate J
    J Pathol; 2003 Jan; 199(1):41-9. PubMed ID: 12474225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uroplakin gene expression by normal and neoplastic human urothelium.
    Lobban ED; Smith BA; Hall GD; Harnden P; Roberts P; Selby PJ; Trejdosiewicz LK; Southgate J
    Am J Pathol; 1998 Dec; 153(6):1957-67. PubMed ID: 9846985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder?
    Riedel I; Liang FX; Deng FM; Tu L; Kreibich G; Wu XR; Sun TT; Hergt M; Moll R
    Eur J Cell Biol; 2005 Mar; 84(2-3):393-405. PubMed ID: 15819416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
    Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation.
    Wu RL; Osman I; Wu XR; Lu ML; Zhang ZF; Liang FX; Hamza R; Scher H; Cordon-Cardo C; Sun TT
    Cancer Res; 1998 Mar; 58(6):1291-7. PubMed ID: 9515818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Origin of the tetraspanin uroplakins and their co-evolution with associated proteins: implications for uroplakin structure and function.
    Garcia-España A; Chung PJ; Zhao X; Lee A; Pellicer A; Yu J; Sun TT; Desalle R
    Mol Phylogenet Evol; 2006 Nov; 41(2):355-67. PubMed ID: 16814572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
    Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
    Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p63 gene expression study and early bladder carcinogenesis.
    Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
    Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer.
    Lu JJ; Kakehi Y; Takahashi T; Wu XX; Yuasa T; Yoshiki T; Okada Y; Terachi T; Ogawa O
    Clin Cancer Res; 2000 Aug; 6(8):3166-71. PubMed ID: 10955799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma.
    Retz M; Lehmann J; Röder C; Plötz B; Harder J; Eggers J; Pauluschke J; Kalthoff H; Stöckle M
    Cancer Res; 1998 Dec; 58(24):5662-6. PubMed ID: 9865718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients.
    Osman I; Kang M; Lee A; Deng FM; Polsky D; Mikhail M; Chang C; David DA; Mitra N; Wu XR; Sun TT; Bajorin DF
    Int J Cancer; 2004 Oct; 111(6):934-9. PubMed ID: 15300806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma.
    Copp HL; Chin JL; Conaway M; Theodorescu D
    Cancer; 2006 Jul; 107(1):60-6. PubMed ID: 16691580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
    Wang D; Wang Z; Tian J; He X; Chowdhury WH; Zhang X; Li S; Rodriguez R
    Urol Oncol; 2010; 28(2):164-9. PubMed ID: 18440837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma.
    Ham WS; Lee JH; Yu HS; Choi YD
    Urology; 2008 Oct; 72(4):921-6. PubMed ID: 18387660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of mouse uroplakin II promoter on human bladder cancer cell line].
    Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Xu CX; Huang GJ; Guo YL
    Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):22-5. PubMed ID: 15059347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
    Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
    Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
    Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
    Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
    Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
    Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC
    Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.